|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Atara Biotherapeutics, Inc. (ATRA) |
|
|
$0.39 0.00 (0.00%) as of 4:30 Tue 6/18
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
108,674,000 |
Market
Cap: |
42.88(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2298 - $2.31 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 707 |
Guru Rank Value : 1.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
816,825 |
816,825 |
Total Buy Value |
$0 |
$0 |
$194,885 |
$194,885 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
4 |
4 |
Total Shares Sold |
211,204 |
267,396 |
419,842 |
591,605 |
Total Sell Value |
$130,313 |
$170,773 |
$340,560 |
$980,941 |
Total People Sold |
5 |
5 |
6 |
9 |
Total Sell Transactions |
5 |
10 |
23 |
41 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Haqq Christopher |
Chief Medical Officer |
|
2015-08-17 |
4 |
AS |
$45.75 |
$73,632 |
D/D |
(1,604) |
245,890 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-08-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
829 |
247,494 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-08-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,907 |
41,532 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-07-31 |
4 |
AS |
$55.41 |
$146,214 |
I/I |
(2,600) |
380,182 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-07-31 |
4 |
AS |
$55.43 |
$138,575 |
D/D |
(2,500) |
246,665 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-07-30 |
4 |
AS |
$56.05 |
$145,946 |
I/I |
(2,600) |
382,782 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-07-17 |
4 |
AS |
$59.90 |
$156,388 |
I/I |
(2,600) |
385,382 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-07-16 |
4 |
AS |
$60.90 |
$159,292 |
I/I |
(2,600) |
387,982 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-07-15 |
4 |
AS |
$62.73 |
$157,353 |
D/D |
(2,500) |
249,165 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-07-01 |
4 |
AS |
$45.25 |
$124,544 |
I/I |
(2,600) |
390,582 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-07-01 |
4 |
AS |
$50.94 |
$129,196 |
D/D |
(2,500) |
251,665 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-06-30 |
4 |
AS |
$51.65 |
$137,616 |
I/I |
(2,600) |
393,182 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-06-18 |
4 |
AS |
$52.62 |
$141,465 |
I/I |
(2,600) |
395,782 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-06-17 |
4 |
AS |
$54.86 |
$143,080 |
I/I |
(2,600) |
398,382 |
|
- |
|
Mcgrath John |
Chief Financial Officer |
|
2015-06-15 |
4 |
AS |
$50.00 |
$500,000 |
D/D |
(10,000) |
27,352 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-06-15 |
4 |
AS |
$44.56 |
$348,116 |
D/D |
(7,500) |
254,165 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-06-05 |
4 |
AS |
$43.74 |
$114,685 |
I/I |
(2,600) |
400,982 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-06-04 |
4 |
AS |
$41.22 |
$159,911 |
I/I |
(3,800) |
403,582 |
|
- |
|
Haqq Christopher |
Chief Medical Officer |
|
2015-06-01 |
4 |
AS |
$40.95 |
$103,665 |
D/D |
(2,500) |
261,665 |
|
- |
|
Mcgrath John |
Chief Financial Officer |
|
2015-05-29 |
4 |
AS |
$40.00 |
$400,000 |
D/D |
(10,000) |
37,352 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-05-22 |
4 |
AS |
$37.40 |
$75,256 |
I/I |
(2,000) |
407,382 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-05-21 |
4 |
AS |
$37.06 |
$74,966 |
I/I |
(2,000) |
409,382 |
|
- |
|
Seidenberg Beth C |
Director |
|
2015-05-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(300,000) |
63,122 |
|
- |
|
Kpcb Xv Founders Fund, Llc |
10% Owner |
|
2015-05-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(300,000) |
63,122 |
|
- |
|
Ciechanover Isaac E. |
Chief Executive Officer |
|
2015-05-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
19,082 |
411,382 |
|
- |
|
736 Records found
|
|
Page 28 of 30 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|